CD8A and neoplasm: However, a recent study reports that PMN-MDSC isolated from tumor-bearing mice treated with ceralasertib, an ATR inhibitor, exhibited a significantly lower suppressive activity against CD8 T cells, and the reduced suppressive activity was associated with up-regulation of type I IFN signature in PMN-MDSC (43).